Three converging signals are flashing on EOSE. Availability has collapsed, borrowing costs have nearly doubled in a month, and options traders just pushed the put-call ratio to a record high.
Availability on EOSE has fallen to just 4.8% of short interest. That means roughly one share remains available for every twenty already borrowed. A month ago, availability sat above 35%. The drop has been relentless — from 29% on June 12 to under 5% today.
Cost to borrow has tracked that squeeze closely. It stood at 0.87% on June 1. It now sits at 2.41% — a 112% rise over 30 days. Two separate CTB pulses fired within three days as the rate accelerated through June.
The borrow market is at its tightest in months. The 52-week availability low is 0.04%, so there is still room to worsen.
Short interest stands at 36.3% of free float. That is a genuinely extreme number. Over 104 million shares are estimated short as of July 1.
The short position has been stable — down roughly 2% over the past month — even as availability has evaporated. That combination is notable. Shorts are not covering. They are holding while the cost to maintain those positions rises sharply.
The ORTEX short score is 72.2, placing EOSE in the 98th percentile for short pressure (utilization rank: 2nd percentile of free shares remaining).
The put-call ratio hit 0.424 on July 2. That is 2.17 standard deviations above the 20-day mean of 0.395 — and the highest level since ORTEX began tracking the name.
The stock itself has lost 42% over the past month. It closed at $5.23 on July 2, down nearly 6% on the day and 14% on the week.
Earnings are scheduled for July 28. The last print on June 3 saw a 14% single-day drop and a 35% decline over the following five days.
CEO Joe Mastrangelo sold 60,703 shares on June 30 at $6.09. The acting CFO and CLO also sold the same day. All three transactions followed share awards granted June 26 — the sells appear to be award-related liquidations rather than discretionary exits, but the timing adds to a negative optics picture.
Analysts are cautious. JP Morgan lowered its target to $6 in April. The consensus mean target sits at $9.63 — well above current prices — but only one analyst carries an outperform rating.
BlackRock added 1.47 million shares as of June 30. That is a notable buy against the prevailing bearish backdrop.
See the live data behind this article on ORTEX.
Open EOSE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
